Merck Puffs Up Respiratory Portfolio With EU Rights To Nycomed's Daxas

Merck acquires rights to the oral COPD medication in Canada and Europe, where approval appears imminent after Daxas received a positive CHMP nod.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet